OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Co. is building a robust pipeline of tumor-agnostic candidates. Co. is developing OKI-219, a selective PI3K?H1047R inhibitor, as its lead program. OKI-219 is being evaluated in a Phase I clinical trial in solid tumor patients with PI3K?H1047R mutations, including breast cancer. We show 3 historical shares outstanding datapoints in our OKUR shares outstanding history coverage, used to compute OKUR market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing OKUR market cap history over the course of time is important for investors
interested in comparing OKUR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of OKUR versus a peer is one thing; comparing
OKUR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like OKUR can fluctuate over the course of history.
With this page we aim to empower investors researching OKUR by allowing them to research the OKUR market cap history. |
Free OKUR Email Alerts:
Video: The Importance of Market Cap
